- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
NanoInk, Inc. announced today the appointment of James M. Hussey, 48, as its Chief Executive Officer, as well as a member of its Board of Directors.
Mr. Hussey joins NanoInk from Ovation Pharmaceuticals, Inc., a leading biopharmaceutical company where he served on the senior management team. Mr. Hussey will be a member of the external Advisory Board of Ovation and remain involved with the company. Mr. Hussey is also an angel investor and has been involved with or founded several early stage biotechnology companies including Silamed Pharmaceuticals, ProCor Pharmaceuticals and Barbeau Pharmaceuticals.
Prior to joining Ovation Pharmaceuticals, Mr. Hussey served as president and chief executive officer of NeoPharm, Inc., a biotechnology company specializing in the research, development and marketing of cancer drugs. Mr. Hussey also served as a director of Option Care, a local pharmacy infusion company, from 1999 until 2004.
Mr. Hussey began his career at Bristol-Myers Squibb in marketing, sales and new business development before being appointed to general manager in 1994. In 1995, he founded and served as chief executive officer of Physicians Quality Care, a physician management services organization in Oak Brook, Ill. which was sold in 1998.
Mr. Hussey received a B.S. degree in Pharmacy from Butler University and a Master of Business Administration degree from University of Illinois at Chicago. He currently serves on the Board of the Illinois Biotechnology Organization.
"We are delighted to have Jim lead the NanoInk team," said Mark Slezak, Chairman of the Company's Board of Directors. "He brings to us over two decades of executive management, product development and marketing leadership at both small and large pharmaceutical companies. His expertise and leadership will help drive NanoInk's growth in the future."
In accepting his appointment, Mr. Hussey said, "I am extremely excited about the opportunities of both Brand Protection and Dip Pen Nanolithography (DPN). NanoInk is a high quality organization with an extremely promising future."
About NanoInk, Inc.
NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the lifescience and semiconductor industries. With DPN, a patented and proprietary nanofabrication technology that allows for unmatched flexibility and accuracy, and also its high-resolution Nanoencryption technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair, and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 issued or pending patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, the University of Illinois at Urbana-Champaign, and the Georgia Institute of Technology.
For more information, please click here
Dresner Corporate Services
Dresner Corporate Services
Copyright © NanoInk, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
RMIT researchers make leap in measuring quantum states July 21st, 2016
Graphene photodetectors: Thinking outside the 2-D box July 21st, 2016